Cargando…
Emodin Reverses Gemcitabine Resistance of Pancreatic Cancer Cell Lines Through Inhibition of IKKβ/NF-κB Signaling Pathway
BACKGROUND: Pancreatic cancer is one of the most malignant tumors, and gemcitabine has been considered as the standard treatment and been widely utilized as a first-line drug for advanced pancreatic cancer, but gemcitabine-resistance always occurs after a short period of treatment. METHODS: Two panc...
Autores principales: | Tong, Hongfei, Huang, Zhen, Chen, Hui, Zhou, Bin, Liao, Yi, Wang, Zhaohong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537840/ https://www.ncbi.nlm.nih.gov/pubmed/33061461 http://dx.doi.org/10.2147/OTT.S253691 |
Ejemplares similares
-
Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro
por: LIU, DIAN-LEI, et al.
Publicado: (2011) -
IKKβ/NF-κB and the miscreant macrophage
por: Timmer, Anjuli M., et al.
Publicado: (2008) -
Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway
por: Wang, Zhaohong, et al.
Publicado: (2019) -
Emodin reverses resistance to gemcitabine in pancreatic cancer by suppressing stemness through regulation of the epithelial‑mesenchymal transition
por: Wei, Weitian, et al.
Publicado: (2022) -
VRK2 activates TNFα/NF-κB signaling by phosphorylating IKKβ in pancreatic cancer
por: Chen, Jionghuang, et al.
Publicado: (2022)